Centessa Pharmaceuticals PLC Form 4 insider transactions

Director Goyal Arjun reports purchasing additional Centessa Pharmaceuticals shares through multiple transactions.

Iqbal Hussain, General Counsel of Centessa Pharmaceuticals, reports the acquisition and disposal of ordinary shares, including transactions under a Rule 10b5-1 trading plan.

Iqbal Hussain, General Counsel of Centessa Pharmaceuticals, reports the sale of ordinary shares acquired through option exercises, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals plc, sold 11,742 ordinary shares at an average price of $13.6141 under a pre-arranged Rule 10b5-1 trading plan.

Centessa Pharmaceuticals' CEO, Saurabh Saha, executed sales of ordinary shares on April 21 and 22, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals, sold 10,000 ordinary shares at an average price of $16.3386, while also exercising options to acquire 10,000 shares at $3.85.

Centessa Pharmaceuticals' CEO, Saurabh Saha, sold 55,000 ordinary shares at an average price of $16.692 per share under a pre-arranged Rule 10b5-1 trading plan.

David Chao, Chief Administrative Officer of Centessa Pharmaceuticals, reports the acquisition and disposition of ordinary shares, including sales under a pre-arranged Rule 10b5-1 trading plan.

Iqbal Hussain, General Counsel of Centessa Pharmaceuticals, reports the exercise of share options and subsequent sale of shares under a pre-arranged trading plan.

Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals, sold 11,494 ordinary shares at an average price of $15.2488 per share on February 25, 2025, under a pre-arranged trading plan.

Centessa Pharmaceuticals CEO Saurabh Saha sold a portion of his holdings in the company's ordinary shares on February 20, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Centessa Pharmaceuticals' General Counsel, Iqbal Hussain, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Karen M. Anderson, Chief People Officer of Centessa Pharmaceuticals, exercised share options and sold a portion of the acquired shares on February 7 and February 10, 2025, according to a Form 4 filing.

John J. Crowley, Chief Financial Officer of Centessa Pharmaceuticals plc, acquired 250,000 share options on February 3, 2025, according to a Form 4 filing with the SEC.

Stephen Kanes, Chief Medical Officer of Centessa Pharmaceuticals, reports the acquisition of 500,000 share options on February 3, 2025.

CEO Saurabh Saha reports disposition of shares to cover tax obligations and acquisition of share options.

Karen M. Anderson, Chief People Officer of Centessa Pharmaceuticals, sold shares to cover tax obligations and acquired new share options.

Iqbal Hussain, General Counsel of Centessa Pharmaceuticals, reports the acquisition and disposal of ordinary shares, including shares withheld for tax obligations and the grant of share options.

Gregory Weinhoff, Chief Business Officer of Centessa Pharmaceuticals, reports disposing of shares to cover tax obligations and receiving a new share option grant.

Tia L. Bush, Chief Technology & Quality Officer of Centessa Pharmaceuticals, reports the acquisition and disposal of ordinary shares, including shares withheld for tax obligations and sales under a Rule 10b5-1 trading plan.

David M. Chao, Chief Administrative Officer of Centessa Pharmaceuticals plc, disposed of shares to cover tax withholding obligations related to vesting restricted share units.

Centessa Pharmaceuticals' Chief Business Officer, Gregory M. Weinhoff, sold 11,742 ordinary shares at an average price of $16.4733 per share, as part of a pre-arranged trading plan.

Centessa Pharmaceuticals CEO, Saurabh Saha, sold a portion of his ordinary shares under a pre-arranged 10b5-1 trading plan.

Iqbal J Hussain, General Counsel of Centessa Pharmaceuticals, sold 6,000 ordinary shares at an average price of $15.29, according to a Form 4 filing.

David Chao, Chief Administrative Officer of Centessa Pharmaceuticals, disposed of 10,385 ordinary shares on December 31, 2024, to cover tax withholding obligations related to vesting restricted share units.

Centessa Pharmaceuticals' Chief Business Officer, Gregory M. Weinhoff, sold 11,742 ordinary shares to cover tax obligations related to vesting restricted share units.

Centessa Pharmaceuticals' General Counsel, Iqbal J Hussain, sold 7,520 ordinary shares to cover tax obligations related to vesting restricted share units.

Centessa Pharmaceuticals CEO, Saurabh Saha, sold 36,263 ordinary shares to cover tax obligations related to vesting restricted share units.

Tia L. Bush, Chief Technology & Quality Officer of Centessa Pharmaceuticals, disposed of 6,419 ordinary shares to cover tax withholding obligations related to vesting restricted share units.

Centessa Pharmaceuticals' Chief Business Officer, Gregory M. Weinhoff, exercised options and sold 10,000 shares of company stock on December 26, 2024.